EU approves Celgene's pomalidomide for multiple myeloma

08/12/2013 | PharmaTimes (U.K.)

Celgene obtained approval from the European Commission to market pomalidomide in combination with dexamethasone for adults with relapsed and refractory multiple myeloma. The drug is specifically indicated for patients who have received at least two therapies and whose disease have worsened with the most recent treatment. The drug will be sold as Imnovid in Europe.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations